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Background : Pregnancy is a physiological process that many women can achieve. Pregnancy in asymptomatic 
patients with cardiomyopathy is usually well tolerated. However, regardless of the poor prognosis, breastfeeding 
cannot be accepted in the restricting form of cardiomyopathy. Prior heart events, inadequate results (NYHA with 
references class III or IV), or advanced left ventricular systolic dysfunction greatly increase the possibility of 
cardiac symptoms in pregnant women. In spite of intense medical care, clinical conditions can worsen during 
pregnancy. Although the incidence of cardiovascular disease is present 0.5-4% in developed countries, our 
knowledge about various cardiomyopathy and pregnancy should be updateable.
Objective : Knowing each type of cardiomyopathy in pregnancy will help the doctor to provide a holistic approach 
to pregnant women
Discussion : Peripartum cardiomyopathy in pregnancy is the most common type of cardiomyopathy; therefore, a 
thorough review is needed to give the best outcome for pregnancy. Arrhythmia is most prevalent in hypertrophic 
cardiomyopathy. Regular monitoring and therapeutic measures should be taken if the arrhythmia is life-threaten-
ing for the mother and child. The commonest form of restrictive cardiomyopathy in pregnancy is cardiac amyloi-
dosis.
Conclusion : Our literature provides three types of cardiomyopathies in pregnancy with an example condition for 





 In general practice, heart disease is expected to be particular-
ly found in pregnant women1.  The study identified elevated rates of 
maternal cardiac adverse effects during birth, including an increased 
risk of maternal mortality. 15% of all births, mostly for heart failure 
care, were complicated by hospital admission for cardiac reasons.1
 Maternal mortality is estimated to be much higher than 
normal in women with coronary disease and the rate tends to escalate 
in such a manner that heart disease is the main cause of maternal death 
in western nations.49 However, any impact of breastfeeding upon on 
development of heart-related disease affects pregnancy is relatively 
unknown.2 
 Cardiomyopathy is characterized as a heart muscle condition 
that causes an irregular myocardium structurally and functionally 
without a specific cause.50 Previous findings have shown that more than 
700 births are well prognosed in 500 women diagnosed with hypertro-
hypertrophic subtype, but in high-risk cases, three deaths have been 
reported. Risk factors include various cases of supraventricular and 
ventricular arrhythmias, congestive heart failure, and ischemic stroke3. 
Far less common and frequently related to systemic disease is restrictive 
cardiomyopathy.51 In peripartum cardiomyopathy, diastolic activity is 
uncommon in most patients with a restricted filling pattern consistent 
with non-segmental hypokinetic in echocardiographic review.4
 The exact prevalence of restrictive cardiomyopathy pattern 
in peripartum cardiomyopathy is unknown because of rare cases 
reported.4 Although the estimated incidence of cardiovascular disease 
in pregnancy is present 0.5-4% in developed countries, our knowledge 
about various of cardiomyopathy and pregnancy should be updated.5
 Our current literature, therefore, aimed to provide three 
types of cardiomyopathies. We provide three types of cardiomyopathies 
in pregnancy with an example condition for each type that is relevant 
during pregnancy. Peripartum cardiomyopathy in pregnancy is the 
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Therefore, a thorough review is needed to give the best outcome for 
pregnancy. Arrhythmia is the commonest form in hypertrophic cardio-
myopathy which need to be regularly monitored and measure should 
be taken if the arrhythmia is life-threatening for mother and the child. 
The normal form of restrictive cardiomyopathy in pregnancy is cardiac 
amyloidosis.
2. Discussion
2.1 Cardiomyopathy and Pregnancy
2.1.1 Definition and Classification of Cardiomyopathy
 Cardiomyopathy (CM) is a myocardial condition in which 
heart muscle structure becomes weakened sufficiently to cause the 
myocardial abnormality observed in the absence of coronary lession, an 
increase of blood pressure, heart valvular disease, and also congenital 
heart disease.6 In 1996, CM was classified into hypertrophic, dilated, 
and restrictive cardiomyopathy subgroups by the World Health Organi-
sation (WHO).7 The cardiomyopathies that happen in pregnant women 
sometimes aren’t well described since the incidences itself are rare.6
2.1.2 Epidemiology of Cardiomyopathy
 In developing countries, cardiovascular disease is found in 
0.5 until 4% of pregnant women.5 The Kaiser Permanente Health 
System, the largest non-profit health plan in the United States, with 9.9 
million participants, presented data from 2003 to 2014 that classified 
pregnant women with heart failure.6 Among these women, 333 (68.2 
percent) had PPCM, 34 (6.9 percent) had non-ischemic cardiomyopa-
thy, and 17 (3.5 percent) had HCM.6 From 2007 to 2011, 1321 women 
with cardiac disease were included in the Registry of Pregnancy and 
Cardiac Disease (ROPAC) survey, a voluntary register for pregnancy 
and cardiac disease run by the Heart Survey Service of the European 
Society of Cardiology. There were 89 patients with cardiomyopathy 
which 32 patients related to DCM, 25 patients related to PPCM, 27 
patients related to HCM, and 5 with other cardiomyopathies.2
2.1.3 Hemodynamic Changes during Normal Pregnancy
 During pregnancy and childbirth, marked differences in 
cardiac output will happen. Each contraction of the uterine can add up 
to 500 milliliters of mother blood volume due to autotransfusion to 
uterine blood.52 The cardiac output will rise by 30 percent during the 
first stage of labor and up to 50 percent in the second stage due to 
mother contraction.9 Cardiac output will enhance the sympathetic surge 
triggered with anxiety and also pain. Rapid plasma volume changes can 
contribute to pulmonary edema in women with cardiomyopathy. 
Epidural anesthesia is also linked to contributing peripheral vasodilata-
tion and intermittent hypotension8. The improvement in stroke volume 
(SV) can be counteracted by blood loss during childbirth, with a mean 
blood loss of 500 ml for an uncomplicated vaginal delivery and 1000 ml 
for a cesarean section8. Cardiac production will increase by 80% over 
pre-labor values immediately after birth due to auto uterine blood 
transfusion also IVC congestion relief.7,8 Systemic venous resistance 
continues to improve and over subsequent days to weeks the cardiac 
output normalizes.5
 Many hemodynamic transitions happened during breastfeed-
ing, which may greatly affect even asymptomatic individuals with 
cardiomyopathy. Due to physiological anemia, the expanding plasma 
volume-related breastfeeding is greater than the increase in haemoglo-
bin.53 Systemic vascular resistance decreases towards the end of the 
second trimester, which then increases towards the end of birth.6,7 
Concentric remodeling and/or slight eccentric hypertrophy of the heart 
leads to a proportional increase in both wall thickness and size of the 
chamber.8 Both the rise in blood volume and circulating levels of sex 
steroid hormones are caused by these changes.8 In particular, progester-
one appears to increase protein synthesis and thus cause hypertrophy in 
heart muscle cells.8
2.2 Dilated Cardiomyopathy in Pregnancy
2.2.1 Definition
 Dilated cardiomyopathy (DCM) is characterized as left 
ventricular and systolic dysfunction dilatation without other causes of 
myocardial dysfunction, such as valvular, congenital, coronary, or 
systemic diseases.9 Several causes are known as DCM etiology, but half 
of all cases are idiopathic10. Idiopathic, myocarditis/infections (viral, 
Lyme and Chagas disease, or HIV), ischemic heart disease, PPCM, 
hypertension, infiltrative sarcoidosis,  inflammatory or autoimmune 
(systemic lupus erythematosus), substance misuse due to alcohol, 
cocaine or amphetamine use, chemotherapy or stroke are the etiology 
of DCM in women with childbearing.11
2.2.2 Hemodynamic Changes in Pregnant Women with DCM
 Women already known to DCM have a restriction on accom-
modating pregnancy, particularly in the time of labor and delivery.54 In 
both times, cardiac output is often increased with increased preload, 
which can worsen heart failure or pulmonary edema.12 These 
limitations become more visible during the labor phase when there is a 
certain significant problem related circulatory system that needs to 
accommodate increasing oxygen demand by increasing cardiac 
output.12 After birth, because of the reduction of the inferior vena cava 
(IVC) compression by the fetus, there is a rapid change in fluid equilib-
rium that instantly raises the preload. Patients related to dilated cardio-
myopathy can have a certain condition such as exacerbation of heart 
failure, edema pulmonum, and also arrhythmias.12 The loss of the 
low-resistance placenta raises the left ventricle afterload after birth, 
which could put women with DCM at higher risk of severe hemodynam-
ic deterioration.54
2.2.3 Planning for Pregnancy, Delivery, and Long-Term Consideration in 
Women with Dilated Cardiomyopathy 
 As pregnancy will change hemodynamic, so women with 
pre-existing DCM should be noticed if she desires to get pregnant.54 
Women with ejection fraction <30% are classified as World Health 
Organization (WHO) with class IV classifications contraindicated to get 
pregnant.55 Pregnancy will alter hemodynamics, but if they try to get 
pregnant, women with pre-existing DCM should be noticed from 
Grewal et al. For females with moderate to severe DCM, progestin-only 
contraceptive is appropriate, due to the high rate of administration 
collapse, oral intake should be stopped56. While pregnancy is not 
advised in some cases, many women have their own decisions. Women 
can take part in monthly follow-up before gestational week 30 and are 
prescribed as a routine before delivery twice a month after that. The 
NT-proBNP value should be used and regularly tracked during the first 
visit.12 To consider pulmonary strain, non-invasive testing such as 
echocardiography may also be effective.12
 Women who have dilated cardiomyopathy are likely to 
deliver by normal vaginal method on the day of birth and the cesarean 
delivery should be reserved when obstetric signs and cardiac dysfunc-
tion appeared.12 Consideration should be extended to anesthetic 
medications to prevent unnecessary myocardial depression caused by 
anesthetic and to minimize the inherent activation of the sympathetic 
involved in the labor.57
 The third trimester and early postpartum cycles should be 
monitored by doctors since there can be an accelerated hemodynamic 
transition.56 Cardiac decompensation, such as deteriorating cardiac  
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failure, may precipitate certain adjustments. But by that time, the 
follow-up is not halted and there may be a late result on the diseased 
ventricle that may develop months after completion of the birth.58 An 
impairment of the ejection fraction and contractility can be associated 
with the late results. It required the discontinuation of optimal medical 
care for HF due to contraindications and/or the choice of a patient 
during breastfeeding and/or lactation.12 
2.2.4 Acute and Chronic Heart Failure Management in Women with 
Pregnancy and DCM  
 In the acute setting, the condition should be divided into 
stable and unstable conditions. Intravenous diuretic and vasodilator 
drugs such as nitroglycerin safely enough to use in pregnancy especially 
in the acute decompensation period.12 Pregnant women with unstable 
hemodynamic may use dobutamine and milrinone. In that condition, 
doctors should have a delivery plan, a cesarean delivery is preferred for 
unstable condition.59 After delivery in the post-partum period, lactation 
should be avoided for the unstable patient. It is different from an 
unstable condition, a stable patient may be addressed to lactation with 
preferences and medication safety profile and initiation of heart failure 
management such as ACE inhibitors, ARBs, beta-blockers, diuretic, or 
digoxin.60  
 The aims of medicinal treatment during breastfeeding are 
close to those of non-pregnant women in terms of chronic illnesses. A 
significant point remains the continuation of treatment. Treatment with 
ACE inhibitors, ARBs, and inhibitors of angiotensin receptor-neprilysin 
(ARNI) is contraindicated in pregnancy due to teratogenic and harmful 
effects on the growth of the fetal kidney, and also spironolactone (FDA 
category C).60 In patients with heart disease during breastfeeding, it is 
safe to treat hypertension with amlodipine.61 Particularly if asymptom-
atic, pregnant women can proceed with β- blockers (BB) for the preven-
tion of persistent heart disease. If necessary, the use of hydralazine and 
nitrates as a vasodilator is necessary as a cure for heart failure.12
2.3 Peripartum Cardiomyopathy
 Examples of dilated cardiomyopathy include peripartum 
cardiomyopathy (PPCM) (DCM). This is a rare disease characterized by 
systolic dysfunction in early or late pregnancy and even postpartum 
periods.13 In the 19th century, PPCM was known as heart disease, but 
the term "peripartum cardiomyopathy" was not used until 1971, when 
Demakis et al. published a broad case series and established the first 
diagnostic criterion which is the progression of heart failure within five 
months of delivery.14
2.3.1 Definition of PPCM
 PPCM is a condition of exclusion attributable to related left 
ventricular systolic dysfunction in women who present with HF which 
should be treated where no other cause is apparent. Therefore, the 
European Society of Cardiology Working Group's 2010 Heart Failure 
Association already revised the term of PPCM to “an idiopathic cardio-
myopathy presenting with HF secondary to LV systolic dysfunction 
towards the end of pregnancy or in the months following delivery, 
where no other cause of heart failure is found”. The criteria for diagnos-
tic shows that LVEF is <45 percent and ventricular dilatation can occur 
or sometimes within normal limit.15
2.3.2 Epidemiology of PPCM
 The highest prevalence of PPCM is in various ethnic groups in 
African Americans (1 in 1421).16 The incidence can be different in 
geographic regions of the world14, in Nigeria the incidence is estimated 
as 1 in 100 deliveries17, 1 in 300 deliveries in Haiti18, and Japan about 1 
in 20,00019.
2.3.3 Risk Factors
 There is a meta-analysis study of 22 reports, which study 
included 979 patients with PPCM, stated that 22 percent of women 
with PPCM had pre-eclampsia, relative to an overall global baseline 
prevalence of 5 percent, and 37 percent had other hypertensive 
disorders.20 Seven percent to 14.5 percent of PPCM patients from the 
United States record multi-gestational pregnancies.20 In 9 percent of 
women, a meta-analysis of 16 PPCM studies found an overall 
prevalence of twin pregnancies relative to the national average of 3 
percent. Half of the PPCM cases occur in women > 30 years of age, and 
1 study recorded that > 40 years of with odds ratio 10 to contract the 
disease relative to women < 20 years of age20.
2.3.4 Pathophysiology of PPCM
 The etiology of PPCM isn’t fully understood and is sometimes 
multifactorial.15 The present theory supports a "two-hit" hypothesis of 
PPCM pathogenesis, whereby cardiomyopathy in women with an 
inherent predisposition is triggered by vascular insult exacerbated by 
anti-vascular or hormonal effects of some phases which are late 
pregnancy and also the early postpartum phase.13
 Any PPCM cluster events in families have long been 
observed.21 Subsequently, in 172 women with PPC, gene sequencing 
associated with DCM observed 26 variants, 65% related TTN; a titin-en-
coding gene.22 Variation of TTN substantially correlates with mutations 
suspected to cause DCM. In comparison, the occurrence of a TTN 
mutation against others expected lower LVEF at 12 months (LVEF at 12 
months 44 percent v 54 percent overall, P=0.005; LVEF at 12 months 
38 percent v 52 percent among black race patients, P=0.04).22 
 A 2007 research indicated that prolactin plays a part in the 
pathogenesis of PPCM, a protein hormone secreted by the anterior 
pituitary. TAT3 is triggered during breastfeeding and the postpartum 
phase in the normal maternal heart13. Via unexplained mechanisms to 
express cathepsin D, an enzyme that cleaves prolactin into a 16 kDa 
segment that causes endothelial apoptosis and capillary drop out, 
oxidative stress stimulates cardiomyocytes. There was an elevated 
expression of 16 kDa prolactin in their cardiomyocytes during mouse 
pregnancy, which lacked STAT313. This mouse had greater coronary 
capillary dropout, increased concentrations of ROS, and the PPCM 
phenotype was also seen. Subsequent research by the same group has 
shown that 16 kDa prolactin exerts cardiotoxic effects by upregulation 
of microRNA-146aa (miRf146a).23 The 16 kDa fragment triggers the 
release of exosomes containing miRf146a and other microRNAs from 
endothelial cells. MiRf146a blocks many pathways that contribute to 
cardiomyocyte death, including Erbb4, Nras, and Notch1. The high 
circulating miRf146a normalizes after bromocriptine administration.13
 Possible shared pathophysiology is indicated by the high 
prevalence of preeclampsia in women with PPCM. Soluble fms-like 
tyrosine kinase receptor 1 (sFlt-1) is a placenta-secreted anti-angiogen-
ic enzyme in rapidly rising levels at the end of pregnancy. Vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF) 
are sequestered by sFlt-1 and are considered to be the primary driver's 
key pathophysiology in pre-eclampsia.24 In addition, sFlt-1 levels in 
women with preeclampsia correlate with global longitudinal pressure 
and increased mass LV25. In normal pregnant women, SFlt-1 levels 
decrease quickly after childbirth (after eliminating the placental source 
of sFlt-1) but appear greater than the normal amount in PPCM 
patients.26
2.3.5 Clinical Presentation and Diagnosis PPCM
The majority of women with PPCM, usually in the first month after 
childbirth, are diagnosed after delivery. Most women have signs 
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and symptoms of HF, including shortness of breath, fatigue, orthopnea, 
chest tightness, edema, and paroxysmal nocturnal dyspnoea. Physical 
testing has also indicated tachypnoea, tachycardia, elevated JVP, 
pulmonary rales, and peripheral oedema15 A left or right side S3 gallop 
(or both) can be audible, but in normal pregnancy, an S3 gallop may 
also be present.13 Sinus tachycardia and nonspecific ST-T wave 
disturbances can be revealed by electrocardiography, as well as left 
ventricular hypertrophy and left atrial enlargement. Vascular conges-
tion, pulmonary edema, and cardiomegaly can be seen in chest X-rays.27 
In any suspected case of PPCM, echocardiography should be conducted 
as the LVEF is normally < 45 percent or fractional shortening < 30 
percent and the LV end-diastolic dimension is > 2.7 cm/m2 .28 Intracar-
diac thrombus can occur, and especially when LVEF is severely reduced, 
the LV apex should be clearly visualized.29 If the echocardiogram is 
ineffective, cardiac magnetic resonance imaging offers precise ejection 
fraction and chamber measurements, but gadolinium is excluded 
during breastfeeding.
2.3.6 Outcome and Prognosis Complication PPCM
 In order to ensure fetal protection, the management of PPCM 
involves special treatment. Many HF drugs are consistent with breast-
feeding after birth.15 The increased prevalence of LV thrombosis and 
systemic thromboembolism has been documented in women with 
PPCM and the hypercoagulable state of pregnancy and the early 
postpartum period.30 Warfarin crosses the placenta for indications other 
than artificial heart valve anticoagulation and is stopped during breast-
feeding. No low-molecular-weight heparin crosses the placenta and can 
be used during breastfeeding. Warfarin and low-molecular heparin are 
both considered healthy for lactation.62
2.3.7 Management of PPCM
 The increased prevalence of LV thrombosis and systemic 
thromboembolism has been reported in women with PPCM and the 
high coagulation state of pregnancy and the early postpartum period.30 
When the LVEF is <30%, anticoagulation is recommended by the 
American Heart Association28, while the European Society of Cardiology 
recommends using LVEF <35% as the criterion.31 Warfarin crosses the 
placenta for indications other than artificial heart valve anticoagulation 
and is stopped during breastfeeding. The placenta is not crossed by 
low-molecular heparin and should be used during breastfeeding.32 With 
lactation, both warfarin and low-molecular-weight heparin are consid-
ered stable. A retrospective registry of 115 German PPCM patients 
indicated that bromocriptine was associated with a higher rate of 
progress in LVEF in comparison to normal treatment, but there was no 
substantial change in overall recovery rates.33 It is important to explore 
with the patient the consequences of not breastfeeding due to 
bromocriptine. A randomized, double-blind, placebo-control trial 
(REBIRTH [Randomized Assessment of Bromocriptine in Myocardial 
Recovery Therapy]) evaluate the impact of bromocriptine on myocardi-
al recovery in 200 women with myocardial recovery and clinical 
outcomes related to PPCM in the United States and Canada has been 
proposed by the IPAC group and is under evaluation. A Class IIb recom-
mendation for the use of bromocriptine is included in ESC recommen-
dations (Figure 1).
 Intravenous vasodilators such as nitroglycerin can be needed 
in the case of acute decompensated HF during pregnancy. The 7 women 
treated with dobutamine had worse results, but selection bias may have 
occurred in this small study. PPCM triggers a total of 60 percent of 
Figure 1. Management of Hypertrophic Cardiomyopathy in Pregnancy. Follow-up patient comprehensively during pregnancy. The target of hemody-
namic is seen in the picture and needs to be evaluate thoroughly during antenatal care and postpartum.48
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cardiogenic shock cases during or immediately after birth.34 Temporary 
mechanical circulatory aid with intra-aortic balloon drive, percutaneous 
ventricular assist device therapy, and extracorporeal membrane 
oxygenation has been successfully utilized in PPCM and should be 
considered early in patients with hemodynamic instability amid inotro-
pic help.
 When and how the delivery of women presenting with PPCM 
during pregnancy should be discussed with the patient and organized 
by a cardio-obstetrics team of specialists from obstetrics, and many 
other related fields.35 Hemodynamic disruption could cause early 
delivery despite medical therapy (or termination if before fetal viabili-
ty). If there are obstetric grounds for cesarean surgery, healthy patients 
are supplied vaginally.15
2.4 Hypertrophy Cardiomyopathy in Pregnancy
2.4.1 Definition and Epidemiology
 The diagnosis of hypertrophic cardiomyopathy (HCM) is 
based on a hypertrophied, non-dilated left ventricle without an exact 
anatomical or physiological finding and, in the absence of another 
cardiac or non-cardiac finding, is detected by echocardiography or 
magnetic resonance imaging (MRI).63 In this case, echocardiographic 
epidemiological tests found an incidence of 1 case per 500 people in the 
general population, but when clinical and genetic diagnoses are mixed, 
cases are identified in 1 case per 200 people. An approximate 750,000 
individuals can be impacted by HCM in the United States. 
However, only a handful of them has been diagnosed with the condition 
(about 100,000), sometimes by means of non-invasive imaging when 
encountered or when there is a low ejection fraction which makes the 
symptom worsen.36
2.4.2 Clinical Imaging
 The characterization of the HCM phenotype is split into two 
general distinctions: the pattern of the hypertrophic wall and the 
outflow obstruction pattern. The discrepancy between these two 
technologies was focused on nearly 50 years of echocardiographic 
imaging. In certain patients, high-resolution tomographic MRI may 
offer a more accurate evaluation of left ventricular hypertrophy and 
even improve stratification assessment by detecting myocardial fibrosis 
in vivo. The thickness of the left ventricular wall is 15 mm or more 
(mean, 21 mm) in most clinically diagnosed cases, although large 
thicknesses (30 to 50 mm) are often known to be hypertrophic wall 
trends. A differential diagnosis of chronic hypertension or physiological 
athlete's heart also includes borderline thickness (13 to 14 mm). In 
certain gene carriers, however, some left ventricular wall thickness is 
compatible with the clinical continuum of HCM, including standard 
measurements. HCM is primarily an obstructive condition, with 70% of 
patients with mechanical impedance to the production of left ventricu-
lar outflow (gradients ≥30 mm Hg) at rest or with physiological 
agitation such as mild strength movement activity. Outflow obstruction 
is normally caused by mitral-valve motion in systolic and septal interac-
tion due to flow drag observed in mitral regurgitation.36 (figure 1)
Figure 2. Hypertrophic cardiomyopathy is primarily diagnosed by echocardiography
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2.5 Arrhythmias in Pregnancy
2.5.1 Definition and Pathophysiology
 Hypertrophic cardiomyopathy (HCM) is described by 
increased LV wall thickness that can’t be clarified by causes of excessive 
loads, such as hypertension or valvular disease. Many women who have 
good functional status and are asymptomatic of HCM can tolerate 
pregnancy and the resulting rise in plasma volume. Adverse effects, 
though, will occur. Counseling for preconception and careful observa-
tion during breastfeeding is important. While no maternal deaths were 
recorded in this registry, heart failure and/or ventricular tachyarrhyth-
mias occurred in many women with HCM. Before birth, women should 
be closely monitored because signs of heart disease or reduced 
functioning status are related to elevated risk during pregnancy.37
 Plasma volume and also cardiac output rise during breast-
feeding. Increased cardiac output is achieved by a larger number of 
strokes in the first and second trimesters, while the heart rate drops 
later in pregnancy. The added pregnancy volume load induces ventricu-
lar cavity enlargement, which may potentially minimize the obstruction 
of the LVOT. The raising cardiac output, however, appears to offset this 
impact, and with progressing gestation, the LVOT gradient also increas-
ing. The same loading volume raises the left atrium distension and 
hence the possibility of atrial fibrillation. Volume fluctuations and 
elevated heart rhythm are not well handled in the sense of diastolic 
disease, aggravating the effects of dyspnea and lowering the threshold 
for developing left heart failure. At birth, a further rise in cardiac 
production is secondary due to blood auto-transfusion from the 
contracting uterus and elevated catecholamine levels. Changes in heart 
rate are often secondary to blood loss, pain, and stress, while expulsion 
helps decrease venous return during contraction. All of these physiolog-
ical changes contribute to a rise in the LVOT gradient and shorten the 
duration of diastolic loading, thereby increasing the risk of pulmonary 
oedema.38 
2.5.2 Clinical Presentation
 Diastolic left ventricular dysfunction is invariably present, 
though some patients often experience systolic dysfunction later in the 
course of the condition. Mitral regurgitation is frequently synonymous 
with LVOT obstruction, often due to mitral valve systolic anterior 
motion (SAM), whereas inherent deficiencies in the mitral valve system 
often contribute to regurgitation of the mitral valve. Dyspnoea and 
chest pain, combined with the pathophysiologic effect of diastolic 
dysfunction, LVOT obstruction, MR, and myocardial ischemia, are the 
most common symptoms. Atrial fibrillation is the most common 
arrhythmia, and the high likelihood of thromboembolism is poorly 
tolerated. There is a growing risk of sudden death in people with a 
family history of sudden death, ventricular tachycardia, syncope, a 
blood pressure response due to exercise, and severe hypertrophy. An 
implantable cardioverter-defibrillator (ICD) will minimize the risk of 
accidental death in this type of patient.39
 It is doubtful that a new arrhythmia substrate will be 
produced by the pregnant state; any physiological changes would 
render a pre-existing substrate capable of sustaining an arrhythmia. A 
bigger heart can tolerate re-entry more efficiently and it is well under-
stood that arrhythmogenic mechanical elongation is. Pregnancy may 
also be the explanation for the onset of arrhythmia. Many tachycardia 
episodes are caused by ectopic beats and the incidence of arrhythmia 
episodes may rise during pregnancy, in line with the increased propen-
sity for ectopic surgery.40
2.5.3 Management of Ventricular Arrhythmia due to Hypertrophic 
Cardiomyopathy in Pregnancy
 During pregnancy, women taking beta-blockers should 
continue to take the drug. For any woman who experiences problems 
during breastfeeding, it is often recommended that she should start a 
beta-blocker and, if possible, prescribe diuretics. A beta-blocker should 
be considered if there is more than mild LVOT obstruction or more than 
15 mm of septal thickness, in order to minimize the possibility of 
pulmonary congestion.41
 Beta-blockers are also useful for regulating and lowering the 
occurrence of ventricular arrhythmias in atrial fibrillation. As there is 
adequate experience of its use in breastfeeding, metoprolol is the 
recommended beta-blocker; however, bisoprolol can also be used. The 
newborn should be treated for bradycardia and hypoglycemia after 
delivery.38
 Verapamil may be used during breastfeeding, but due to the 
possibility of fetal atrioventricular blockage, caution is required. Since 
it can cause fetal thyroid disorders, amiodarone should not be used 
unless strictly necessary. During breastfeeding, Sotalol may be used. 
Finally, in the event of a maternal emergency, any drug that is toxic to 
the child should not be refused. Atrial fibrillation is poorly tolerated 
and, either chemically or electrically, involves prompt cardioversion to 
preserve sinus rhythm. Electrical cardioversion during pregnancy is 
deemed healthy, but regular monitoring of the fetal heart rate and the 
prospect of an immediate cesarean operation should be given when the 
fetus is at a viable age.42  
2.6 Restrictive Cardiomyopathy in Pregnancy
2.6.1 Definition and Epidemiology
 In restricted cardiomyopathy, nondilated left or right ventri-
cles with diastolic dysfunction or both systolic and diastolic dysfunction 
are characterized by nondilated left or right ventricles without any 
other associated cardiac or systemic diseases. A heterogeneous commu-
nity of myocardial diseases that differ in clinical appearance and 
another clinical subset of restrictive cardiomyopathies are. Restrictive 
cardiomyopathy is complicated by enhanced myocardial stiffness and 
decreased elasticity as recoil results in recent decreased ventricular 
loading and ejection fraction.43
 Genes that are active in hereditary RCM specifically encode 
cardiac sarcomere proteins. There is no maternity data available for 
RCM patients. This is because RCM is very unusual and the RCM 
treatment path is always serious with a bad prognosis.44
2.6.2 Clinical Imaging
 In restricted cardiomyopathy (RCM), a patient with normal 
or near-normal systolic activity and signs of diastolic dysfunction with a 
restrictive echocardiography filling pattern should be suspected of 
being diagnosed. 2-dimensional and Doppler echocardiography are 
important for the assessment of diastolic dysfunction and the differenti-
ation between patients with RCM and patients with other restricted 
physiology due to constrictive pericarditis. The echo indicates concen-
trated thickening of the free wall and septum of the LV and suggests 
anomalies of geographic wall displacement in non-coronary delivery 
and aneurysms. In restricted cardiomyopathy, the strain phenomenon 
corresponds to the deformation of the myocardium at contraction with 
any percentage length change. Strain imaging has been tested by tissue 
Doppler imaging in the early stages, but non-Doppler speckle-tracking 
strain imaging has become a common method with the aid of non-an-
gle-dependent measurements.45
2.7 Cardiac Amyloidosis in Pregnancy
2.7.1  Definition and Pathophysiology
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 This is the most prevalent form of restrictive cardiomyopathy 
by far, and when explaining restrictive cardiomyopathy, the 
overwhelming majority of the study relates to cardiac amyloidosis. This 
form of cardiac activity, however, induces both diastolic and systolic left 
ventricular dysfunction, which is most commonly found in moderately 
dilated cardiomyopathies. Interstitial penetration of the atria and 
ventricles while the heart is involved leads in the more advanced 
situations to a solid and 'rubbery' quality of the myocardium. Systemic 
amyloidosis is a protein metabolism condition in which abnormal 
extracellular protein content is accumulated in tissues and organs. This 
produces substantial morbidity and is typically fatal. Light chain 
amyloid also involves the heart, leading to congestive heart failure.46
 This amyloid infiltration mechanism is responsible for the 
marked thickening of the echocardiographic vision of the left and right 
ventricular walls, regular or reduced LV cavity size, and decreased 
diastolic and systolic LV function. The coronary intramural arteries and 
the conductive system are often infiltrated and this accounts for the 
electrocardiographic irregularities found in the first-degree A-V block. 
The endocardium may also be compromised and can be associated with 
the overlying thrombus. Amyloid heart infiltration often leads to focal 
or diffuse valve thickening, but clinical valve dysfunction is uncom-
mon.44
2.7.2 Clinical Presentation
 The biopsy will only specifically classify cardiac amyloidosis 
and the echocardiographic features of both types can be distinguished. 
Amyloid penetration echocardiographic findings consist of: I thickened 
RV, (ii) thickened LV walls, (iii) 'granular' or 'sparkling' (ground glass) 
myocardial appearance, (iv) normal or minimal LV cavity size, (v) 
expanded atria, and (vi) decrease LV systolic and diastolic function.46 
2.7.3 Management of Cardiac Amyloidosis in Pregnancy
 Volume management (diuretics/salt restriction) and arrhyth-
mia management are primarily involved in the cardiac-specific 
treatment of all types of amyloidosis. Usually used in HF, neurohormon-
al antagonists are often poorly tolerated and detrimental. Beta-block-
ers, ACE inhibitors, and ARBs, in particular, frequently contribute to 
hypotension (due to autonomic instability and the existence of a narrow 
left ventricular cavity with an inability to raise the volume of stroke in 
response to vasodilation) and beta-blockers often intensify bradyar-
rhythmias. Digoxin binds to amyloid fibrils, contributing even at usual 
circulating levels to the risk for digoxin toxicity, which should be 
usually avoided. Pregnancy in this patient is not appropriate, so 
terminating is the choice of care and multidisciplinary consultation is 
compulsory.47
3. Conclusion
 Pregnant women with cardiomyopathy may have a form of 
cardiomyopathy that is dilated, hypertrophic or restricting. Peripartum 
cardiomyopathy, which is a dilated type of cardiomyopathy, is the most 
prevalent type of cardiomyopathy in pregnancy. In general, except for 
restrictive cardiomyopathy, cardiomyopathy that happened during 
pregnancy may be safely handled medically with no risk to the mother 
or fetus. Where practicable, medications should be prevented in the first 
trimester and the treatment preference should indicate the safety 
record in pregnancy as well as the precise type of cardiomyopathy being 
treated and any underlying heart condition associated with it. Drugs 
should be supplied at the lowest effective dosage and closely supervised 
for the mother and her baby during pregnancy.
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